Finance

Lists
Why is MGNX up 2,39%?
Dive Deeper
MGNX:NASDAQ
MacroGenics Inc
USD 3,86
+2,39%
(+0,090) 1D
USD 3,86
0,00% (0,00)
After hours
Closed: 30 Sep., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGNX...
Open
USD 3,76
High
USD 3,91
Low
USD 3,73
Mkt. cap
245,88 m
Avg. vol.
501,32 k
Volume
634,05 k
52-wk high
USD 5,08
52-wk low
USD 1,30
EPS
-USD 0,23
Beta
1,22
Shares outstanding
63,70 m
No. of employees
293
Open
USD 3,76
High
USD 3,91
Low
USD 3,73
Mkt. cap
245,88 m
Avg. vol.
501,32 k
Volume
634,05 k
52-wk high
USD 5,08
52-wk low
USD 1,30
EPS
-USD 0,23
Beta
1,22
Shares outstanding
63,70 m
No. of employees
293
About MacroGenics Inc
CEO-
Employees293
Founded2000
HeadquartersRockville, Maryland, Verenigde State van Amerika
Sector-
Websitemacrogenics.com
Analyst ratings
Based on 4 analysts giving stock ratings to MGNX in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MGNX in the last 3 months.
Highest
Current USD 3,86
USD 11,00 (+184,97%)
Average
USD 7,00 (+81,35%)
Lowest
USD 4,00 (+3,63%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mayank Mamtani
B. Riley Securities
Buy
Maintained
USD 11,00
+185%
08/17/2026
Stephen Willey
Stifel Nicolaus
Hold
Reiterated
USD 4,00
+3,6%
08/14/2026
Etzer Darout
Barclays
Buy
Maintained
USD 6,00
+55,4%
08/14/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
08/13/2026
Robert Burns
H.C. Wainwright
Hold
Reiterated
-
-
05/07/2026
Last report
13 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 1,14 / USD 0,26
+341,36%beat
Revenue / Est. (USD)
32,83 m / 59,14 m
-44,48%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
72,84 m
41,23 m
6,72 m
32,83 m
Cost of goods sold
44,30 m
44,09 m
34,97 m
38,78 m
Cost of revenue
44,30 m
44,09 m
34,97 m
38,78 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,90 m
9,24 m
9,71 m
7,90 m
Operating expense
9,90 m
9,24 m
9,71 m
7,90 m
Total operating expenses
54,20 m
53,32 m
44,68 m
46,68 m
Operating income
18,64 m
-12,10 m
-37,96 m
-13,85 m
Other non operating income
-
-
-
-
EBT including unusual items
16,82 m
-14,93 m
-41,30 m
-69,64 m
EBT excluding unusual items
16,82 m
-14,93 m
-41,30 m
-16,88 m
Income tax expense
-
-777,00 k
-
-
Effective tax rate
-
5,20%
-
-
Other operating expenses
-
-
-
-
Net income
16,82 m
-14,16 m
-36,77 m
19,52 m
Net profit margin
23,09%
-34,33%
-547,15%
59,44%
Earnings per share
0,27
-0,22
-0,58
1,14
Interest and investment income
1,53 m
1,44 m
1,55 m
1,37 m
Interest expense
-3,34 m
-4,27 m
-4,89 m
-4,40 m
Net interest expenses
-1,81 m
-2,84 m
-3,34 m
-3,03 m
Depreciation and amortization charges
-
-
-
-
EBITDA
20,42 m
-10,39 m
-36,28 m
-13,14 m
Gain or loss from assets sale
-
-10,00 k
-
-94,49 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme